tbuckley/cabot-search huggingface dataset:
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
Authors: V De Stefano, A M Vannucchi, M Ruggeri, F Cervantes, A Alvarez-Larrán, A Iurlo, M L Randi, L Pieri, E Rossi, P Guglielmelli, S Betti, E Elli, M C Finazzi, G Finazzi, E Zetterberg, N Vianelli, G Gaidano, I Nichele, D Cattaneo, M Palova, M H Ellis, E Cacciola, A Tieghi, J C Hernandez-Boluda, E Pungolino, G Specchia, D Rapezzi, A Forcina, C Musolino, A Carobbio, M Griesshammer, T Barbui
Journal: Blood Cancer Journal (2016)

Abstract We retrospectively studied 181 patients with polycythaemia vera ( n =67), essential thrombocythaemia ( n =67) or primary myelofibrosis ( n =47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd–Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62), splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per 100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new antithrombotic drugs and JAK-2 inhibitors.
Legal opinion throws status of living wills of patients in vegetative state into doubt
Authors: Clare Dyer
Journal: BMJ (2016)

A legal provision that obliges doctors to honour a patient’s “living will” refusing artificial nutrition and hydration seems to conflict with a Court of Protection practice direction stating that all cases concerning the withdrawal of life sustaining treatment from patients in a vegetative or minimally conscious state should go to court, a senior judge has pointed out.1

The Mental Capacity Act 2005 provides that a valid advance decision to refuse a specified treatment, made when the patient had capacity to make it, should be complied with by doctors …
Immunological Function against Human T-Lymphotrophic Virus Type I in Carriers with Collagen Diseases and HAM/TSP.
Authors: Tomohiro Kozako, Makoto Yoshimitsu, Masaki Akimoto, Kakushi Matsushita, Yohann White, Shingo Toji, Shuji Izumo, Shunro Sonoda, Naomichi Arima
Journal: Blood (2008)
Lenalidomide Synergistically Enhances the Effect of Dendritic Cell Vaccination in Mouse Multiple Myeloma Model
Authors: Thanh-Nhan Nguyen-Pham, Sung-Hoon Jung, Manh-cuong Vo, Hyun Ju Lee, My-Dung Hoang, Nuri Choi, Hyeoung-Joon Kim, Je-Jung Lee
Journal: Blood (2012)
Prognostic Impact of the Detection of the WT1 Gene mRNA with Peripheral Blood in Adult Acute Myeloid Leukemia (AML).
Authors: Shuichi Miyawaki, Nahoko Hatsumi, Toshiharu Tamaki, Tomoki Naoe, Keiya Ozawa, Kunio Kitamura, Takahiro Karasuno, Kinuko Mitani, Yoshihisa Kodera, Tamotsu Yamagami, Daisuke Koga
Journal: Blood (2005)
Elevated tricuspid regurgitant jet velocity, reduced forced expiratory volume in 1 second, and mortality in adults with sickle cell disease
Authors: Shruti Chaturvedi, Djamila Labib Ghafuri, Adetola Kassim, Mark Rodeghier, Michael R. DeBaun
Journal: American Journal of Hematology (2017)

Cardiopulmonary disease is the leading cause of mortality in adults with sickle cell disease (SCD). Elevated tricuspid regurgitant jet velocity (TRJV) and reduced forced expiratory volume in 1 second (FEV 1 ) %predicted are associated with early mortality in SCD; however their relationship and combined effect on survival is unknown. We investigated the relationship between TRJV and FEV 1 %predicted, and their combined effect on mortality, in a retrospective cohort of 189 adults with SCD who underwent both pulmonary function testing and echocardiography. Nineteen (9.9%) of 189 patients died over a median follow‐up of 1.4 years; cardiopulmonary disease was the major cause of death in 52.6%. FEV 1 %predicted was negatively associated with TRJV (Spearman rho, −0.34, P &lt; 0.001). Individuals with FEV 1 %predicted ≤70% were more likely to have an elevated TRJV ≥2.5 m/second, compared to those with FEV 1 %predicted &gt;70% [45.8% versus 17.1%; odds ratio (OR) 4.1 (95% Confidence interval ([CI] 2.1–8.0); P = 0.001]. In a multivariable cox regression model, the combination of TRJV ≥2.5 m/second and FEV 1 %predicted ≤70% predicted earlier mortality [hazard ratio (HR) 4.97 (95% CI 1.30‐18.91; P = 0.019)] after adjusting for age, sex, and nephropathy. Both FEV 1 %predicted ≤70% and TRJV ≥2.5 m/second were independently associated with nephropathy [OR 4.48 (95% CI 1.51–13.31); P = 0.004] and [OR 3.27 (95% CI 1.19–9.00); P = 0.017], respectively. In conclusion, pulmonary and cardiac impairment are associated with, and contribute to mortality in SCD. Therapies aimed at improving reduced FEV 1 %predicted and elevated TRJV could improve survival in patients with SCD. Am. J. Hematol. 92:125–130, 2017. © 2016 Wiley Periodicals, Inc.
Myeloid Cells in Peripheral Blood Mononuclear Cell (PMBC) Concentrates Inhibit the Expansion of Chimeric Antigen Receptor (CAR) T Cells
Authors: David F. Stroncek, Daniel W. Lee, Jiaqiang Ren, Marianna Sabatino, Hanh Khuu, Melinda S. Merchant, Crystal L. Mackall
Journal: Blood (2015)
Protein-Z Deficiency and/or Protein Z Polymorphisms in First Trimester Pregnancy Complications
Authors: Maria Topalidou, Vassilios K Papadopoulos, Zoi Mpousiou, Haris Kartsios, Kyriaki Kokoviadou, Sofia Vakalopoulou, Emmanouil Papadakis, Anna Kioumi, Ioannis Korantzis, Vassilia Garipidou, Panteleimon A Chaloudis
Journal: Blood (2011)
TMOD-02BLOCKING CXCR4 INCREASES SURVIVAL IN A MOUSE MODEL OF NEURAL STEM CELLS-DERIVED GLIOBLASTOMA BY BLOCKING AN AUTOCRINE POSITIVE FEEDBACK LOOP REGULATING APOPTOSIS AND CELL CYCLE PROGRESSION VIA Rb1 AND cdk4/cdk6/CyclinD1
Authors: Alexandra Calinescu, Erica Carballo, Dustin Tran, Daniel Zamler, Robert Doherty, Pedro Lowenstein, Maria Castro
Journal: Neuro-Oncology (2015)
Characterization Of The HLA Class II Ligandome In Acute Myeloid Leukemia (AML) Reveals Novel Candidates For Peptide-Based Immunotherapy
Authors: Juliane S. Stickel, Claudia Berlin, Daniel J. Kowalewski, Lothar Kanz, Helmut R. Salih, Hans-Georg Rammensee, Stefan Stevanovic
Journal: Blood (2013)
US transplant study may have violated federal rules
Authors: Michael McCarthy
Journal: BMJ (2016)

A large study assessing whether inducing hypothermia in brain dead organ donors would affect graft function in recipients of kidney transplants may have violated federal regulations by not considering the organ recipients as human participants, an investigation has found.1 The investigation was conducted by the US Department of Veterans Affairs’ Office of Research Oversight.

In the study, published in the New England Journal of Medicine in 2015,2 organ donors, after declaration of neurologic death, were randomly assigned to being cooled to 34°C to 35°C, the “mild hypothermia” group, or to be maintained at 36.5°C to 37.5°C, the “normothermia” group, pending organ harvesting. The trial’s main outcome measure was whether hypothermia reduced the rate of delayed graft function in the organ recipients, defined as the requirement for dialysis in the first week after transplantation.

The trial was terminated early on the recommendation of an independent data and safety monitoring board, after an interim analysis showed efficacy of hypothermia. At …
NIMG-10ASSESSMENT OF BEVACIZUMAB RESISTANCE RELATED WITH EXPRESSION OF BRANCHED-CHAIN AMINO ACID TRANSAMINASE-1 IN ISOCITRATE DEHYDROGENASE-1 WILD-TYPE GLIOBLASTOMA: APPLICATION OF DSC MR IMAGING
Authors: Hye Rim Cho, Seung Hong Choi, Chul-Kee Park, Sung-Hye Park, Hyeonjin Kim
Journal: Neuro-Oncology (2015)

PURPOSE: To investigate the bevacizumab resistance related with expression of branched-chain amino acid transaminase 1(BCAT1) in isocitrate dehydrogenase-1(IDH1) wild-type glioblastoma(GBM) in a rat model, which was evaluated by using DSC MR perfusion, and to correlate the expression level of BCAT1 with cerebral blood volume(CBV) in GBM patients. MATERIALS AND METHODS: This study was approved by the animal care committee for animal study and the institutional review board for human study at our institute. We established IDH1 wt expressing U87 human GBM cell line with or without BCAT1 knockdown(IDH1 wt + shBCAT1, and IDH1 wt, respectively), and confirmed the BCAT1 knockdown by western blot. For in vivo animal study, U87 cells were implanted intracerebrally in nude rats; IDH1 wt and IDH1 wt + shBCAT1. All 12 rats underwent pre-treatment DSC-MRI 14 days after tumor implantation using 9.4T MRI, and then received bevacizumab twice for a week. Then, the brain was isolated for histological analysis after post-treatment DSC-MRI. In terms of GBM patients, the expression level of BCAT1 was correlated with CBV from pre-operative DSC MRI. RESULTS: BCAT1 suppression inhibits cell proliferation and limits cell migration potential in vitro. In vivo MR study, tumor size of the IDH1 wt tumors were significantly increased than those with BCAT1 knockdown. The CBV ratio between before and after bevacizumab treatment shows IDH1 wt tumors were significantly higher compare with those with BCAT1 knockdown. In histological analysis, micro vessels reformation by bevacizumab resistance were observed more in IDH1 wt tumors than those with BCAT1 knockdown. The expression level of BCAT1 was correlated with CBV in GBM patients. CONCLUSIONS: BCAT1 expression in IDH1 wt GBM is related with the bevacizumab resistance, which could be assessed by DSC MRI. This study shows that CBV can be a surrogate imaging biomarker for the prediction of antiangiogenic treatment in GBM.
Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenström Macroglobulinemia: Preliminary Results.
Authors: Irene M. Ghobrial, Xavier Leleu, Nancy Rubin, Marybeth Nelson, Renee Leduc, Diane Warren, Jana Allen, Sue Lovecchio, Jacob Soumerai, Peter Sportelli, Robert Birch, Craig Henderson, Steven P. Treon, Paul Richardson, Kenneth C. Anderson
Journal: Blood (2007)
Unusual Pulmonary Lesions
Authors: Sandeep T. Laroia, Anil Potti, Mojdeh Rabbani, Syed A. Mehdi, Michael Koch
Journal: Journal of Clinical Oncology (2002)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2002.20.11.2749 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12039939 Unusual Pulmonary Lesions Case 3. Pulmonary Vein Leiomyosarcoma Presenting as a Left Atrial Mass Sandeep T. LaroiaxSandeep T. LaroiaSearch for articles by this author , Anil PottixAnil PottiSearch for articles by this author , Mojdeh RabbanixMojdeh RabbaniSearch for articles by this author , Syed A. MehdixSyed A. MehdiSearch for articles by this author , Michael KochxMichael KochSearch for articles by this author Show More University of North Dakota, Veterans’ Affairs Medical Center, and MeritCare Medical Center, Fargo, ND https://doi.org/10.1200/JCO.2002.20.11.2749 First Page Full Text PDF Figures and Tables © 2002 by American Society of Clinical Oncology
Smoking Cessation, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Authors: Peter G. Shields, Roy S. Herbst, Douglas Arenberg, Neal L. Benowitz, Laura Bierut, Julie Bylund Luckart, Paul Cinciripini, Bradley Collins, Sean David, James Davis, Brian Hitsman, Andrew Hyland, Margaret Lang, Scott Leischow, Elyse R. Park, W. Thomas Purcell, Jill Selzle, Andrea Silber, Sharon Spencer, Tawee Tanvetyanon, Brian Tiep, Hilary A. Tindle, Reginald Tucker-Seeley, James Urbanic, Monica Webb Hooper, Benny Weksler, C. Will Whitlock, Douglas E. Wood, Jennifer Burns, Jillian Scavone
Journal: Journal of the National Comprehensive Cancer Network (2016)

Cigarette smoking has been implicated in causing many cancers and cancer deaths. There is mounting evidence indicating that smoking negatively impacts cancer treatment efficacy and overall survival. The NCCN Guidelines for Smoking Cessation have been created to emphasize the importance of smoking cessation and establish an evidence-based standard of care in all patients with cancer. These guidelines provide recommendations to address smoking in patients and outlines behavioral and pharmacologic interventions for smoking cessation throughout the continuum of oncology care.
International Prognostic Index, Serum IgA Level, and Monocytes Count Are Independently Associated with Overall Survival in Patients with HTLV-I-Negative Nodal Peripheral T-Cell Lymphoma
Authors: Aiko Kato, Yukihiro Imai, June Takeda, Nobuhiko Yamauchi, Yuki Funayama, Kazunari Aoki, Yuichiro Ono, Sumie Tabata, Noboru Yonetani, Akiko Matsushita, Takayuki Ishikawa
Journal: Blood (2012)
Demographic, tumor characteristics, and outcomes associated with SMAD4 mutation in colorectal cancer.
Authors: Amir Mehrvarz Sarshekeh, Michael J. Overman, Bryan K. Kee, David R. Fogelman, Arvind Dasari, Kanwal Pratap Singh Raghav, Eduardo Vilar Sanchez, Shanequa Manuel, Imad Shureiqui, Robert A. Wolff, Keyur Patel, Rajyalakshmi Luthra, Kenna Rael Shaw, Cathy Eng, Dipen M. Maru, Mark Routbort, Funda Meric-Bernstam, Scott Kopetz
Journal: Journal of Clinical Oncology (2016)

565 Background: SMAD4 regulates signaling in TGF-β pathway as inactivation of SMAD4 renders resistance of cells to TGF-β1-induced growth inhibition. Sporadic mutation of SMAD4 has been reported to be present in 8.6-25% of colorectal cancers (CRC), but the clinicopathologic features and outcomes associated with this mutation have not been described. Methods: Data for patients (pts) with metastatic or locally advanced unresectable CRC who received treatment at MD Anderson Cancer Center whose tumors underwent genotyping for SMAD4 mutation were reviewed and clinicopathologic characteristics, and survival outcomes were evaluated. Tumors were sequenced using a hotspot panel (Ion Torrent, Life Technology) predicted to cover 80% of the reported mutations in SMAD4, and further targeted resequencing that included full-length SMAD4 was performed on mutated ones by HiSeq (Illumina) with full exome coverage to an average depth of 800. Results: Among 616 pts (47.4% females) with CRC, 11.2% of pts (n = 69) had SMAD4 mutation by hotspot testing. SMAD4 mutation was associated with colon cancer versus rectal cancer (OR = 2.1, p = 0.01) and female gender (15% vs 8%, OR = 2.12, p = 0.004). There was no association between the presence of SMAD4 mutation and age, stage at the presentation, tobacco history, colonic location, presence of distant metastasis, histology, nor tumor grade. When compared to pts with wild-type SMAD4, those with SMAD4 mutation had shorter survival from date of testing (median survival of 20.2 months versus 14 months, respectively; log-rank, HR = 1.4, p = 0.014). Full-length sequencing was performed on mutated tumors and it confirmed that missense mutations in R361 and P356 in the MH2 domain were the most common, which are predictive of disruption of both homo- and hetero-oligomerization required for activation. Conclusions: This study is the largest retrospective study to date characterizing SMAD4 mutation in metastatic CRC, and demonstrates a prognostic role for this subgroup of CRC. The prevalence and spectrum of SMAD4 mutations is consistent with previous studies and data from TCGA. Further studies are required to evaluate the implication of the dysregulated TGF- β pathway on response to therapy.
Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells
Authors: Santhana G. T. Devaraj, Warren Fiskus, Bhavin Shah, Sunil Sharma, Jun Qi, Baohua Sun, Saikat Saha, Swaminathan Padmanabhan Iyer, Youli Zu, James Bradner, Kapil N. Bhalla
Journal: Blood (2014)
Sarcopenia Is Risk Factor for Development of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Placement
Authors: Silvia Nardelli, Barbara Lattanzi, Sabrina Torrisi, Francesca Greco, Alessio Farcomeni, Stefania Gioia, Manuela Merli, Oliviero Riggio
Journal: Clinical Gastroenterology and Hepatology (2016)
Identity matters to individuals: Group assessment cannot be reduced to collective performance
Authors: Catherine Belzung, Etienne Billette de Villemeur, Anouk Grevin, Gennaro Iorio
Journal: Behavioral and Brain Sciences (2016)

Abstract Although we agree that both identification and differentiation play a key role in explaining individual behaviour in groups, we suggest that (1) cohesion and differentiation should be better articulated, (2) the proposal carries implicit value choices that are not necessarily universal, and (3) the success of a group in shaping individual behaviour should refer to the values of individual members.
High Non-Relapse Mortality and Low Relapse Incidence in Sex-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation From Female Donor with Male Child
Authors: Akihito Shinohara, Nobuhiro Hiramoto, Saiko Kurosawa, Ryosuke Ueda, Takashi Tanaka, Kohei Tada, Yujin Kobayashi, Noriyuki Morikawa, Keiji Okinaka, Kinuko Tajima, Takuya Yamashita, Mineo Kurokawa, Takahiro Fukuda
Journal: Blood (2012)
Unusual Sites of Involvement by Hematologic Malignancies
Authors: Odeta Lapkuviene, Derrick Forchetti, Janet E. Roepke
Journal: Journal of Clinical Oncology (2001)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2001.19.19.3988 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11579120 Unusual Sites of Involvement by Hematologic Malignancies Case 1. Intravascular Large B-Cell Lymphoma Presenting With CNS Symptoms Odeta LapkuvienexOdeta LapkuvieneSearch for articles by this author , Derrick ForchettixDerrick ForchettiSearch for articles by this author , Janet E. RoepkexJanet E. RoepkeSearch for articles by this author Show More Ball Memorial Hospital, Muncie, IN https://doi.org/10.1200/JCO.2001.19.19.3988 First Page Full Text PDF Figures and Tables © 2001 by American Society of Clinical Oncology
Combination of Lenalidomide, Melphalan, Prednisone and Thalidomide (RMPT) in Relapsed/Refractory Multiple Myeloma: Results of a Multicenter Phase II Clinical Trial
Authors: Antonio Palumbo, Patrizia Falco, Grazia Sanpaolo, Antonietta Falcone, Vincenzo Ferderico, Letizia Canepa, Monica Crugnola, Luca Baldini, Alessandra Larocca, Valeria Magarotto, Maria Teresa Petrucci, Mario Boccadoro
Journal: Blood (2008)
Transplantation of Primary Human CD34+CD38 - Hematopoietic Stem Cells Recapitulates Idiopathic Myelofibrosis in the NOD/scid/IL2rgKO Mice.
Authors: Noriyuki Saito, Fumihiko Ishikawa, Kazuya Shimoda, Shuro Yoshida, Yoriko Saito, Mitsuhiro Fukata, Noriaki Kawano, Leonard D. Shulz, Koichi Akashi, Mine Harada
Journal: Blood (2007)
Multislice Multiecho T2* Cardiovascular Magnetic Resonance Detects Heterogeneous Myocardial Iron Distribution in Thalassemia Patients
Authors: Vincenzo Positano, Alessia Pepe, Anna Ramazzotti, Maria Filomena Santarelli, Antonella Meloni, Anna Spasiano, Caterina Borgna-Pignatti, Paolo Cianciulli, Marcello Capra, Maria-Eliana Lai, Aurelio Maggio, Massimo Lombardi, Luigi Landini
Journal: Blood (2008)
High Levels of Circulating HSP70 Levels in Patients with Chronic Myeloid Leukemia and Correlation with Resistance to Therapy with Imatinib.
Authors: Richard Tseng, Chen-Hsiung Yeh, Iman Jilani, Zhong Zhang, Hagop Kantarjian, Jorge Cortes, Susan O’Brien, Francis Giles, Alison Hannah, Zeev Estrov, Michael Keating, Maher Albitar
Journal: Blood (2007)
The hows and whys of “we” (and “I”) in groups
Authors: Amanda J Barnier, Celia B Harris, John Sutton
Journal: Behavioral and Brain Sciences (2016)

Informed by our interdisciplinary research program on collaborative recall, we argue that Baumeister et al. should consider: (1) group success as a balance between differentiation and integration (not differentiation alone); (2) variation in constellations of people and processes within and across groups; and (3) nuanced measurement of what people bring to, do in, and get out of groups.
Strategies and factors associated with preparing for competing in the heat: a cohort study at the 2015 IAAF World Athletics Championships
Authors: Julien D Périard, Sébastien Racinais, Toomas Timpka, Örjan Dahlström, Armin Spreco, Jenny Jacobsson, Victor Bargoria, Karin Halje, Juan-Manuel Alonso
Journal: British Journal of Sports Medicine (2016)

Assess exertional heat illness (EHI) history and preparedness in athletes competing in a World Athletics Championships under hot/humid conditions and identify the factors associated with preparedness strategies.Of the 207 registered national teams invited to participate in the study, 50 (24%) accepted. The 957 athletes (49% of all 1965 registered) in these teams were invited to complete a precompetition questionnaire evaluating EHI history, heat stress prevention (heat acclimatisation, precooling and hydration) and recovery. Responses from 307 (32%) athletes were separated in field events, sprints, middle-distance and long-distance running, and decathlon/heptathlon for analysis.48% of athletes had previously experienced EHI symptoms and 8.5% had been diagnosed with EHI. 15% heat acclimatised (∼20 days) before the championships. 52% had a precooling strategy, ice slurry ingestion (24%) being the most prevalent and women using it more frequently than men (p=0.005). 96% of athletes had a fluid consumption strategy, which differed between event categories (p<0.001). The most common volumes planned on being consumed were 0.5-1 L (27.2%) and ≥2 L (21.8%), water being the most frequent. 89% of athletes planned on using at least one recovery strategy. Female sex (p=0.024) and a previous EHI diagnosis increased the likelihood of using all 3 prevention strategies (p<0.001).At a World Championships with expected hot/humid conditions, less than one-fifth of athletes heat acclimatised, half had a precooling strategy and almost all a hydration plan. Women, and especially athletes with an EHI history, were more predisposed to use a complete heat stress prevention strategy. More information regarding heat acclimatisation should be provided to protect athlete health and optimise performance at major athletics competitions in the heat.